[1]
|
Arbeit, J.M., Howley, P.M. and Hanahan, D. (1996) Chronic Estrogen-Induced Cervical and Vaginal Squamous Carcinogenesis in Human Papillomavirus Type 16 Transgenic Mice. Proceedings of the National Academy of Sciences of the United States of America, 93, 2930-2935. https://doi.org/10.1073/pnas.93.7.2930
|
[2]
|
Moreno, V., Bosch, F.X., Muñoz, N., et al. (2002) Effect of Oral Contraceptives on Risk of Cervical Cancer in Women with Human Papillomavirus Infection: The IARC Multicentric Case-Control Study. The Lancet, 359, 1085-1092.
https://doi.org/10.1016/S0140-6736(02)08150-3
|
[3]
|
Luhn, P., et al. (2013) The Role of Co-Factors in the Progression from Human Papillomavirus Infection to Cervical Cancer. Gynecologic Oncology, 128, 265-270. https://doi.org/10.1016/j.ygyno.2012.11.003
|
[4]
|
Gadducci, A., Cosio, S. and Fruzzetti, F. (2020) Estro-Progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. Anticancer Research, 40, 5995-6002. https://doi.org/10.21873/anticanres.14620
|
[5]
|
Brake, T. and Lambert, P.F. (2005) Estrogen Contributes to the Onset, Persistence, and Malignant Progression of Cervical Cancer in a Human Papillomavirus-Transgenic Mouse Model. Proceedings of the National Academy of Sciences of the United States of America, 102, 2490-2495. https://doi.org/10.1073/pnas.0409883102
|
[6]
|
Ramírez-López, I.G., Ramírez de Arellano, A., Jave-Suárez, L.F., Hernández-Silva, C.D., García-Chagollan, M., Hernández-Bello, J., Lopez-Pulido, E.I., Macias-Barragan, J., Montoya-Buelna, M., Muñoz-Valle, J.F. and Pereira-Suárez, A.L. (2019) Interaction between 17β-Estradiol, Prolactin and Human Papillomavirus Induce E6/E7 Transcript and Modulate the Expression and Localization of Hormonal Receptors. Cancer Cell International, 19, 227.
https://doi.org/10.1186/s12935-019-0935-6
|
[7]
|
Riera Leal, A., Ortiz-Lazareno, P.C., Jave-Suárez, L.F., Ramírez De Arellano, A., Aguilar-Lemarroy, A., Ortiz-García, Y.M., Barrón-Gallardo, C.A., Solís-Martínez, R., Luquin De Anda, S., Muñoz-Valle, J.F. and Pereira-Suárez, A.L. (2020) 17β-Estradiol-Induced Mitochondrial Dysfunction and Warburg Effect in Cervical Cancer Cells Allow Cell Survival under Metabolic Stress. International Journal of Oncology, 56, 33-46. https://doi.org/10.3892/ijo.2019.4912
|
[8]
|
Gustafsson, J.A. (1999) Estrogen Receptor Beta—A New Dimension in Estrogen Mechanism of Action. Journal of Endocrinology, 163, 379-383. https://doi.org/10.1677/joe.0.1630379
|
[9]
|
Chung, S.H. and Lambert, P.F. (2009) Prevention and Treatment of Cervical Cancer in Mice Using Estrogen Receptor Antagonists. Proceedings of the National Academy of Sciences of the United States of America, 106, 19467-19472.
https://doi.org/10.1073/pnas.0911436106
|
[10]
|
Chung, S.H., Wiedmeyer, K., Shai, A., Korach, K.S. and Lambert, P.F. (2008) Requirement for Estrogen Receptor Alpha in a Mouse Model for Human Papillomavirus-Associated Cervical Cancer. Cancer Research, 68, 9928-9934.
https://doi.org/10.1158/0008-5472.CAN-08-2051
|
[11]
|
Son, J., Park, Y. and Chung, S.H. (2018) Epithelial Oestrogen Receptor α Is Dispensable for the Development of Oestrogen-Induced Cervical Neoplastic Diseases. The Journal of Pathology, 245, 147-152.
https://doi.org/10.1002/path.5069
|
[12]
|
Lee, S.A., Baik, S. and Chung, S.H. (2021) Functional Roles of Female Sex Hormones and Their Nuclear Receptors in Cervical Cancer. Essays in Biochemistry, 65, 941-950. https://doi.org/10.1042/EBC20200175
|
[13]
|
Wang, C., Zhang, T., Wang, K., Zhang, S., Sun, Q. and Yang, X. (2021) ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen via HMGA2. Frontiers in Oncology, 11, Article ID: 712849.
https://doi.org/10.3389/fonc.2021.712849
|
[14]
|
孙清. 雌激素受体ER-α36对宫颈癌生物学行为的影响及机制研究[D]: [博士学位论文]. 济南: 山东大学, 2018.
|
[15]
|
Sun, Q., Liang, Y., Zhang, T., Wang, K. and Yang, X. (2017) ER-α36 Mediates Estrogen-Stimulated MAPK/ERK Activation and Regulates Migration, Invasion, Proliferation in Cervical Cancer Cells. Biochemical and Biophysical Research Communications, 487, 625-632. https://doi.org/10.1016/j.bbrc.2017.04.105
|
[16]
|
Bologa Cristian, G., et al. (2006) Virtual and Biomolecular Screening Converge on a Selective Agonist for GPR30. Nature Chemical Biology, 2, 207-212. https://doi.org/10.1038/nchembio775
|
[17]
|
Revankar, C.M., Cimino, D.F., Sklar, L.A., Arterburn, J.B. and Prossnitz, E.R. (2005) A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling. Science, 307, 1625-1630. https://doi.org/10.1126/science.1106943
|
[18]
|
李敏, 闫楠, 唐荣荣, 瞿全新, 钮硙硙, 刘佳佳, 王玉亮. GPR30在宫颈癌细胞生长中的作用及其机制研究[J]. 现代妇产科进展, 2015, 24(1): 18-21.
|
[19]
|
Friese, K., Kost, B., Vattai, A., et al. (2018) The G Protein-Coupled Estrogen Receptor (GPER/GPR30) May Serve as a Prognostic Marker in Early-Stage Cervical Cancer. Journal of Cancer Research and Clinical Oncology, 144, 13-19.
https://doi.org/10.1007/s00432-017-2510-7
|
[20]
|
刘智博. 宫颈癌与正常宫颈组织中ER、GPR30表达情况的相关研究[D]: [博士学位论文]. 北京: 北京协和医学院, 2015.
|
[21]
|
Ino, Y., Akimoto, T., Takasawa, A., Takasawa, K., Aoyama, T., Ueda, A., Ota, M., Magara, K., Tagami, Y., Murata, M., Hasegawa, T., Saito, T., Sawada, N. and Osanai, M. (2020) Elevated Expression of G Protein-Coupled Receptor 30 (GPR30) Is Associated with Poor Prognosis in Patients with Uterine Cervical Adenocarcinoma. Histology and Histopathology, 35, 351-359.
|